(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.96% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 283.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.35%.
Teva Pharmaceutical Industries's revenue in 2025 is $16,776,000,000.On average, 7 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,857,165,717,696, with the lowest TEVA revenue forecast at $18,917,541,340,368, and the highest TEVA revenue forecast at $20,679,767,278,800. On average, 7 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,923,708,103,392, with the lowest TEVA revenue forecast at $18,799,371,241,632, and the highest TEVA revenue forecast at $20,842,681,395,504.
In 2027, TEVA is forecast to generate $20,256,420,031,872 in revenue, with the lowest revenue forecast at $18,976,052,748,480 and the highest revenue forecast at $21,186,866,149,104.